Sunday , October 17 2021

Bliss GVS Pharma soars as its arm receives compliant certification from USFDA

Bliss GVS Pharma is currently trading at Rs. 102.45, up by 1.20 points or 1.19% from its previous closing of Rs. 101.25 on the BSE.

The scrip opened at Rs. 105.90 and has touched a high and low of Rs. 105.90 and Rs. 102.25 respectively. So far 53978 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 190.00 on 05-Nov-2018 and a 52 week low of Rs. 73.90 on 23-Aug-2019.

Last one week high and low of the scrip stood at Rs. 105.10 and Rs. 98.90 respectively. The current market cap of the company is Rs. 1060.35 crore.

The promoters holding in the company stood at 41.53%, while Institutions and Non-Institutions held 28.89% and 29.57% respectively.

Bliss GVS Pharma’s 70% subsidiary — Kremoint Pharma has received a compliant certification from the US Food and Drug Administration (USFDA) that was based on the inspection conducted at the company’s facility located at M.I.D.C, Ambernath (East), Thane-District, during the period June 17, 2019-June 20, 2019.

Bliss GVS Pharma is engaged in the manufacture of a wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.

Please share this news
<div id="taboola-below-article-thumbnails"></div>
<script type="text/javascript">
  window._taboola = window._taboola || [];
    mode: 'thumbnails-a',
    container: 'taboola-below-article-thumbnails',
    placement: 'Below Article Thumbnails',
    target_type: 'mix'